Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.03)
# 3,566
Out of 4,829 analysts
110
Total ratings
25.26%
Success rate
-14.58%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $115.71 | +38.28% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $118.17 | +86.17% | 21 | May 2, 2025 | |
| CRVO CervoMed | Maintains: Buy | $12 → $21 | $8.49 | +147.35% | 5 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $7.87 | +217.66% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.17 | +278.55% | 5 | Mar 13, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $23 → $15 | $3.79 | +295.78% | 3 | Feb 28, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $9 → $8 | $6.57 | +21.77% | 5 | Feb 12, 2025 | |
| CYBN Cybin | Maintains: Buy | $86 → $73 | $7.05 | +935.46% | 7 | Feb 12, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $1.53 | +5,128.76% | 7 | Jan 6, 2025 | |
| GHRS GH Research | Maintains: Buy | $31 → $28 | $10.38 | +169.75% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $1.39 | +691.37% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $2.63 | +3,055.89% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $6.15 | +127.64% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $9.36 | +113.68% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $26 | $1.53 | +1,599.35% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $17.44 | +89.22% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $20.24 | +641.11% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $16.93 | - | 2 | Jan 31, 2017 |
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $115.71
Upside: +38.28%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $118.17
Upside: +86.17%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $12 → $21
Current: $8.49
Upside: +147.35%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $7.87
Upside: +217.66%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.17
Upside: +278.55%
COMPASS Pathways
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $3.79
Upside: +295.78%
Sage Therapeutics
Feb 12, 2025
Maintains: Hold
Price Target: $9 → $8
Current: $6.57
Upside: +21.77%
Cybin
Feb 12, 2025
Maintains: Buy
Price Target: $86 → $73
Current: $7.05
Upside: +935.46%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.53
Upside: +5,128.76%
GH Research
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $10.38
Upside: +169.75%
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $1.39
Upside: +691.37%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $2.63
Upside: +3,055.89%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $6.15
Upside: +127.64%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $9.36
Upside: +113.68%
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $1.53
Upside: +1,599.35%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $17.44
Upside: +89.22%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $20.24
Upside: +641.11%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $16.93
Upside: -